Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer?-Reference-Cited by-同舟云学术

Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer?

Published:2006-09 Issue:7 Volume:1 Page:684-691
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Kurata Takayasu,Matsuo Keitaro,Takada Minoru,Kawahara Masaaki,Tsuji Masahiro,Matsubara Yuka,Otani Nagahiro,Matsuyama Shigeki,Muraishi Kenya,Fujita Tetsuya,Ishikawa Masato,Koyano Keita,Okamoto Isamu,Satoh Taroh,Tamura Kenji,Nakagawa Kazuhiko,Fukuoka Masahiro

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference65 articles.

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

2. Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group

3. Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial

4. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

5. Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib;Journal of Cancer Research and Clinical Oncology;2012-07-05

2. A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction;Investigational New Drugs;2011-08-24

3. Principles of Systemic Chemotherapy for Squamous Cell Head and Neck Cancer;Head and Neck Cancer;2011

4. Tratamento do carcinoma pulmonar de não pequenas células, doença avançada, com erlotinib em segunda e terceira linhas. A propósito de dois casos clínicos;Revista Portuguesa de Pneumologia;2008-10